Budesonide multi-matrix system formulation for treating ulcerative colitis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 6, 2014, Pages 741-743

  Prantera, Cosimo ^a   Scribano, Maria Lia ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Budesonide; Local therapy; Multi matrix system; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; BUDESONIDE; MESALAZINE;

DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; MAINTENANCE THERAPY; REMISSION; REVIEW; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; GLUCOCORTICOIDS; HUMANS;

EID: 84896460388     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.884072     Document Type: Review

References (15)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-25
2. Sherlock ME, Seow CH, Steinhart AH, et al. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;(10):CD007698
3. Lindgren S, Lofberg R, Bergholm L, et al. Effect of budesonide enema on remission and relapse rate in distal ulceratice colitis and proctitis. Scand J Gastroenterol 2002;37:705-10
4. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx: inflamm Bowel Dis. 2005;11:421-7
5. Sandborn WJ, Travis S, Moro L, et al. V® Once-daily budesonide MMX extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143:1218-26
6. Travis SPL, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2013. [Epub ahead of print]
7. D'Haens GR, Kovacs A, Vergauwe P, et al. Clinical trial: preliminary efficacy and safety study of a new budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010;4:153-60
8. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100:2478-85
9. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007;21:827-34
10. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009;137:1934-43
11. Feagan BG, MacDonald JK. Oral 5-Aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000544
12. Lichtenstein GR, Bengtsson B, Hapten-White L, et al. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safey analysis. Aliment Pharmacol Ther 2009;29:643-53
13. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol 2002;97:915-21
14. Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;(1):CD002913
15. Sandborn WJ, Danese S, Ballard ED, et al. Efficacy of budesonide MMx 6 mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology 2012;142(5):S-564